The Senate Attacks on Pharma Put the Industry in Jeopardy and Consumers at Risk
Singling out an industry segment won’t solve the underlying problem of healthcare costs.
New Novo Nordisk Ozempic Data Build Case for Adding Kidney Disease to Label
Blockbuster Novo Nordisk drug Ozempic now has clinical trial results showing statistically significant reductions in the risk of kidney disease progression. The company said these results support the expansion of the drug’s label to chronic kidney disease.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Novo Nordisk Plans €2B Site Expansion as GLP-1 Drug Demand Grows
Novo Nordisk's planned expansion will more than double the footprint of its France production site, bringing new capacity for manfacturing GLP-1 drugs for metabolic conditions. The location is already one of the company’s largest for making diabetes products.
Weight Loss Startup Calibrate Is Changing Hands
Weight loss company Calibrate — which sells a program combining GLP-1 drugs with personalized metabolic health coaching — announced a legal restructuring of its business. The startup, which recently had two major rounds of layoffs, has struggled amid GLP-1 drug shortages and mounting user complaints.
Report: Weight Loss Drugs Cost Significantly More for Americans than Peer Countries
A new KFF analysis compared list prices for Ozempic, Wegovy, Rybelsus and Mounjaro. It found that the U.S. has much higher list prices for these drugs than other peer countries while also having the highest rate of obesity.
Which Drugs Are Driving Next Year’s 3.42% Increase in Hospital Pharmacy Spend?
Hospitals’ pharmacy spending is projected to rise by 3.42% next year, according to a new report. Specialty drugs, including Ozempic and Humira, as well as neurology medications are the primary drivers of this increase in pharmacy expenses.
The Impact Brands: Empowering Wellness Through Natural and Holistic Solutions
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
Coalition Applauds Reintroduction of Obesity Treatment Bill, Urges Passage
The Treat and Reduce Obesity Act would expand Medicare coverage for obesity screenings, treatments and therapies like anti-obesity medications. The Health Equity Coalition for Chronic Disease came out in favor of the bill and asked for swift passage.
Medical Expenses Will Rise by 7% Next Year, Report Predicts
New research predicts that healthcare costs will increase by 7% next year. The estimate is higher than the projected medical cost trends in 2022 and 2023 — which were 5.5% and 6.0%, respectively.
LifeMD Launches GLP-1 Weight Management Program
Through LifeMD's new weight management program, consumers can gain access to GLP-1 prescriptions like Ozempic and Wegovy, clinical support, lab testing, education and more.
In the GLP-1 Era, Clinical Guidelines for Obesity Care Are Urgently Needed
While the attention GLP-1s are receiving is exciting for medical professionals like me who've specialized in obesity treatment for decades, with little fanfare, the ‘miracle drug’ message is misleading and harmful.
At ViVE 2024, Panelists Share Prior Authorization Progress and Frustration in Payer Insights Program
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.